---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-24-001908"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2024-12-18T23:59:59+00:00"
generated_at: "2026-05-29T01:56:30.485643+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexaria Bioscience signs ~AUD$5.1M clinical study agreement with Novotech for GLP-1-H24-4 trial

## Summary
- Effective Dec 2, 2024: Novotech as CRO for DehydraTECH Cannabidiol + GLP-1 agonists in pre- and Type II Diabetes.
- Aggregate costs ~AUD$5.1 million; upfront payments ~AUD$414,600 (direct) and ~AUD$347,800 (pass-through).
- Lexaria AU can terminate the Project Agreement with or without cause upon 90 days' notice.
- Initial start-up work already completed under a separate Start-Up Agreement.

## SEC filing metadata
- accession: 0001640334-24-001908
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2024-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.0
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001908/0001640334-24-001908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033424001908/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-24-001908
- JSON: https://secwatch.observer/filing/0001640334-24-001908.json
- Plain text: https://secwatch.observer/filing/0001640334-24-001908.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.